-

HCA SHAREHOLDER ALERT: HCA Healthcare, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of HCA Healthcare, Inc. (“HCA Healthcare” or the “Company”) (NYSE: HCA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On July 14, 2026, HCA Healthcare issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA Healthcare sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company’s payer mix, driven by an increase in uninsured volume—primarily due to patients who had lost coverage on health insurance exchanges—which impacted revenue by approximately $400 million in the quarter. The Company lowered its forecast for 2026 earnings to between $28.70 and $30.50 a share and narrowed its revenue target to $77 billion to $79.5 billion from a prior $76.5 billion to $80 billion range. Adjusted earnings before interest, taxes, depreciation and amortization are targeted at between $15.4 billion and $16.1 billion, where HCA Healthcare previously anticipated $15.55 billion to $16.45 billion.

On this news, HCA Healthcare’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. Click here to learn more about securities class actions.

If you purchased or otherwise acquired HCA Healthcare securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT THE INVESTIGATION]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

NYSE:HCA

Release Versions
$Cashtags

Contacts

More News From Kirby McInerney LLP

CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 14, 2026, Celcuity issued a press release announcing that it had secured U.S. Food and Drug Administrati...

INVESTOR ALERT: Securities Class Action Filed Against Wise Group plc – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Wise Group plc (“Wise” or the “Company”) (NASDAQ: WSE) common stock between May 11, 2026 and July 23, 2026, inclusive (“the Class Period”).If you suffered a loss on your Wise investments, you have until September 29, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. If yo...

INVESTOR ALERT: Securities Class Action Filed Against Capricor Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) common stock between December 17, 2025 and July 26, 2026, inclusive (“the Class Period”).If you suffered a loss on your Capricor investments, you have until September 28, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted...
Back to Newsroom